Page 298 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 22 Natural Killer Cell Immunity 246.e3

103. Kim DH, Sohn SK, Lee NY, et al: Transplantation with higher dose 117. Ansell SM, Witzig TE, Kurtin PJ, et al: Phase I study of interleukin-12
of natural killer cells associated with better outcomes in terms of non- in combination with rituximab in patients with B-cell non-Hodgkin
relapse mortality and infectious events after allogeneic peripheral blood lymphoma. Blood 99:67, 2002.
stem cell transplantation from HLA-matched sibling donors. Eur J 118. Sentman CL, Barber MA, Barber A, et al: NK cell receptors as tools in
Haematol 75:299, 2005. cancer immunotherapy. Adv Cancer Res 95:249, 2006.
104. Rosenberg SA, Lotze M, Muul L, et al: A progress report on the treat- 119. Aversa F, Tabilio A, Velardi A, et al: Treatment of high risk acute
ment of 157 patients with advanced cancer using lymphokine-activated leukemia with T-depleted stem cells from related donors with one fully
killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J mismatched HLA haplotype. N Engl J Med 339:1186, 1998.
Med 316:889, 1987. 120. Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural
105. Miller JS, Tessmer-Tuck J, Pierson BA, et al: Low dose subcutaneous killer cell alloreactivity in mismatched hematopoietic transplants.
interleukin-2 after autologous transplantation generates sustained in Science 295:2097, 2002.
vivo natural killer cell activity. Biol Blood Marrow Transplant 3:34, 1997. 121. Bellucci R, Alyea EP, Chiaretti S, et al: Graft-versus-tumor response in
106. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al: Successful adoptive patients with multiple myeloma is associated with antibody response
transfer and in vivo expansion of human haploidentical NK cells in to BCMA, a plasma-cell membrane receptor. Blood 105:3945,
patients with cancer. Blood 105:3051, 2005. 2005.
107. Shah N, Martin-Antonio B, Yang H, et al: Antigen presenting cell- 122. Kruger N, Shaw B, Iacobelli S, et al: Comparison between anti-
mediated expansion of human umbilical cord blood yields log-scale thymocyte globulin and alemtuzumab and the possible impact of KIR-
expansion of natural killer cells with anti-myeloma activity. PLoS ONE ligand mismatch after dose-reduced conditioning and unrelated stem
8:e76781, 2013. cell transplantation in patients with multiple myeloma. Br J Haematol
108. Leung W: Infusions of allogeneic natural killer cells as cancer therapy. 129:631, 2005.
Clin Cancer Res 20:3390, 2014. 123. Koh CY, Blazar BR, George T, et al: Augmentation of antitumor effects
109. Farag SS, George SL, Lee EJ, et al: Postremission therapy with low-dose by NK cell inhibitory receptor blockade in vitro and in vivo. Blood
interleukin 2 with or without intermediate pulse dose interleukin 2 97:3132, 2001.
therapy is well tolerated in elderly patients with acute myeloid leukemia: 124. Romagne F, Andre P, Spee P, et al: Preclinical characterization of 1-7F9,
Cancer and Leukemia Group B study 9420. Clin Cancer Res 8:2812, a novel human anti-KIR receptor therapeutic antibody that augments
2002. natural-killer mediated killing of tumor cells. Blood 114:2667, 2009.
110. Bernstein ZP, Porter MM, Gould M, et al: Prolonged administration 125. Benson DM, Hofmeister CC, Padmanabhan S, et al: A phase 1 trial
of low-dose interleukin-2 in human immunodeficiency virus-associated of the anti-KIR antibody IPH2101 in patients with relapsed/refractory
malignancy results in selective expansion of innate immune effectors myeloma. Blood 120:4324, 2012.
without significant clinical toxicity. Blood 86:3287, 1995. 126. Vey N, Bourhis JH, Boissel N, et al: A phase 1 trial of the anti-
111. Shah MH, Freud AG, Benson DM, Jr, et al: A phase I study of ultra low inhibitory KIR mAb IPH2101 for AML in complete remission. Blood
dose interleukin-2 and stem cell factor in patients with HIV infection 120:4317, 2012.
or HIV and cancer. Clin Cancer Res 12:3993, 2006. 127. Von Strandmann EP, Hansen HP, Reiners KS, et al: A novel bispecific
112. Khan KD, Emmanouilides C, Benson DM, Jr, et al: A phase 2 study protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer
of rituximab in combination with recombinant interleukin-2 for (NK) cells and CD138 activates NK cells and has potent antitumor
rituximab-refractory, indolent non-Hodgkin lymphoma. Clin Cancer activity against human multiple myeloma in vitro and in vivo. Blood
Res 12:7046, 2006. 107:1955, 2006.
113. Margolin KA: Interleukin-2 in the treatment of renal cancer. Semin 128. Gleason MK, Ross JA, Warlick ED, et al: CD16xCD33 bispecific
Oncol 27:194, 2000. killer cell engager (BiKE) activates NK cells against primary MDS and
+
114. Conlon KC, Lugli E, Welles HC, et al: Redistribution, hyper- MDSC CD33 targets. Blood 123:3016, 2014.
proliferation activation of natural killer cells and CD8 T cells, and 129. Muller N, Michen S, Tietze S, et al: Engineering NK cells modified
cytokine production during first-in-human clinical trial of recombinant with an EGFRvIII-specific chimeric antigen receptor to overexpress
human interleukin-15 in patients with cancer. J Clin Oncol 33:74, CXCR4 improves immunotherapy of CXCL12/SDF-1α secreting
2015. glioblastoma. J Immunother 38:197, 2015.
115. Xu W, Jones M, Liu B, et al: Efficacy and mechanism-of-action of 130. Chu J, Deng Y, Benson DM, et al: CS1-specific chimeric antigen recep-
a novel superagonist interleukin-15: interleukin-15 receptor γSu/Fc tor (CAR)-engineered natural killer cells enhance in vitro and in vivo
fusion complex in syngeneic murine models of multiple myeloma. antitumor activity against human multiple myeloma. Leukemia 28:917,
Cancer Res 73:3075, 2013. 2014.
116. Carson WE, Parihar R, Lindemann MJ, et al: Interleukin-2 enhances 131. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of human-
the natural killer cell response to Herceptin-coated Her2/neu-positive ized anti-CD20 monoclonal antibody and polymorphism in IgG Fc
breast cancer cells. Eur J Immunol 31:3016, 2001. receptor FcγRIIIa gene. Blood 99:754, 2002.